JMP Securities cut shares of Savara (NASDAQ:SVRA) from an outperform rating to a market perform rating in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has $2.60 price objective on the stock.
Several other research firms have also commented on SVRA. Zacks Investment Research lowered shares of Savara from a hold rating to a sell rating in a research note on Thursday, February 21st. Roth Capital set a $10.00 price target on shares of Savara and gave the company a hold rating in a research report on Tuesday, May 14th. Canaccord Genuity set a $22.00 price target on shares of Savara and gave the company a buy rating in a research report on Monday, March 25th. LADENBURG THALM/SH SH restated a buy rating and issued a $21.00 price target on shares of Savara in a research report on Monday, April 1st. Finally, BidaskClub upgraded shares of Savara from a hold rating to a buy rating in a research report on Friday, April 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. Savara has an average rating of Hold and an average price target of $8.10.
SVRA stock traded up $0.02 on Thursday, hitting $2.64. 7,146 shares of the company’s stock traded hands, compared to its average volume of 311,851. Savara has a 1-year low of $2.55 and a 1-year high of $14.06. The firm has a market cap of $378.73 million, a PE ratio of -2.04 and a beta of 0.95. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.05 and a quick ratio of 12.05.
In other Savara news, CFO David L. Lowrance sold 7,500 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares in the company, valued at approximately $22,062.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $9.03, for a total transaction of $225,750.00. Following the completion of the sale, the insider now owns 184,754 shares of the company’s stock, valued at approximately $1,668,328.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,261 shares of company stock valued at $744,174. 6.50% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its position in Savara by 12.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 11,550 shares of the company’s stock worth $85,000 after buying an additional 1,279 shares in the last quarter. Citigroup Inc. increased its stake in shares of Savara by 23.1% during the 1st quarter. Citigroup Inc. now owns 8,377 shares of the company’s stock worth $62,000 after purchasing an additional 1,570 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Savara by 19.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,300 shares of the company’s stock worth $141,000 after purchasing an additional 2,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Savara by 3.5% during the 4th quarter. Bank of New York Mellon Corp now owns 82,940 shares of the company’s stock worth $628,000 after purchasing an additional 2,830 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Savara by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 84,850 shares of the company’s stock worth $625,000 after purchasing an additional 3,670 shares during the last quarter. Institutional investors own 45.71% of the company’s stock.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.